The outcome

Legit.Health is building the category-defining clinical-intelligence layer for dermatology, as an independent company at scale. The exit thesis is not "sell early"; it is "build a must-own asset."

Strategic appetite for clinical AI is real

Clinical-AI platforms are being acquired at scale by large healthcare players. Roche's 2026 agreement to acquire the digital-pathology AI company PathAI (up to roughly $1B) is a clear recent signal of strategic-acquirer appetite for this kind of asset. We treat it as a market signal, not a valuation benchmark.

A rich acquirer landscape

Legit.Health sits at the intersection of several buyer universes, some of which already overlap with current commercial partners. A large independent outcome does not depend on any single acquirer.

Pharmaceutical companies

A pharma acquiring the platform to own objective endpoint measurement across its trials and its dermatology franchise.

CROs & clinical-research groups

Clinical-research organisations adding AI-based endpoint measurement and data services to their trial offering.

Telehealth & virtual-care platforms

Large telehealth and virtual-care players that need a clinical-grade dermatology layer they cannot build in the required timeframe.

Health systems & payers

Integrated providers and insurers embedding a clinical-grade dermatology layer across their provider networks.

Big diagnostics & digital pathology

The Roche / PathAI precedent: large diagnostics acquiring clinical-AI platforms at scale.

Dermatology imaging & diagnostics

Device and imaging players adding an AI/software layer to defend and expand their install base.

Our stance

• Not for sale now. Series A capital funds the path to a larger, independent outcome.
• Optionality by design. We are building to scale independently; a strategic transaction remains a credible alternative, on our timing and terms, not under pressure.

What this means for an investor

A large-outcome ambition in a category with real strategic-acquirer appetite (the Roche / PathAI precedent), and optionality in both directions: you are not betting on a single exit path, and you are not entering a company that needs to sell.